Broglio Kathleen, Matzo Marianne
Kathleen Broglio is an NP in the Section of Palliative Medicine and an assistant professor of medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Marianne Matzo is director of research for the Hospice and Palliative Nurses Association, Pittsburgh, PA. She is an AJN contributing editor and coordinates Perspectives on Palliative Nursing. Contact author: Marianne Matzo,
Am J Nurs. 2018 Oct;118(10):30-38. doi: 10.1097/01.NAJ.0000546378.81550.84.
: Medication-assisted treatment for opioid use disorder (OUD), which incorporates methadone, buprenorphine, or naltrexone, has been shown to reduce all-cause mortality rates in patients with this disease-and the numbers of patients receiving such treatment is substantial. In 2016, among U.S. patients with OUD, nearly 350,000 were treated with methadone, more than 60,000 were treated with buprenorphine, and more than 10,000 were treated with naltrexone. Managing acute pain in patients receiving this treatment can be a significant nursing challenge. The authors discuss the attributes of the three medications used to treat OUD and, through a composite patient case, review how to manage acute pain effectively in patients receiving this type of treatment.This article is one in a series on palliative care developed in collaboration with the Hospice and Palliative Nurses Association (https://advancingexpertcare.org), which offers education, certification, advocacy, leadership, and research on palliative care.
用于治疗阿片类物质使用障碍(OUD)的药物辅助治疗,包括美沙酮、丁丙诺啡或纳曲酮,已被证明可降低该疾病患者的全因死亡率,且接受此类治疗的患者数量可观。2016年,在美国患有OUD的患者中,近35万人接受了美沙酮治疗,6万多人接受了丁丙诺啡治疗,1万多人接受了纳曲酮治疗。对接受这种治疗的患者进行急性疼痛管理可能是一项重大的护理挑战。作者讨论了用于治疗OUD的三种药物的特性,并通过一个综合病例,回顾了如何有效地对接受此类治疗的患者进行急性疼痛管理。本文是与临终关怀和姑息护理护士协会(https://advancingexpertcare.org)合作编写的关于姑息治疗系列文章之一,该协会提供有关姑息治疗的教育、认证、宣传、领导力和研究。